COVID-19 has changed the way we work and live. In response to the public health emergency, Milken Institute Chairman Michael Milken is engaging a range of industry leaders and medical experts to help us better understand and confront a crisis that has not only altered our current day-to-day but will change the course of how we work, socialize, and fight disease for years to come.
All content for Conversations with Mike Milken is the property of Milken Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
COVID-19 has changed the way we work and live. In response to the public health emergency, Milken Institute Chairman Michael Milken is engaging a range of industry leaders and medical experts to help us better understand and confront a crisis that has not only altered our current day-to-day but will change the course of how we work, socialize, and fight disease for years to come.
Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky
Conversations with Mike Milken
27 minutes 52 seconds
4 years ago
Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky
Albert Bourla
Chairman and CEO, Pfizer
Alex Gorsky
Chairman and CEO, Johnson & Johnson
“I think history has shown us to have major leaps forward almost after every crisis. Whether it's a war, a natural disaster, or frankly a big challenge such as going to the moon, these kinds of inflection points force us to go in new directions to collaborate and to accelerate technological breakthroughs.” – Alex Gorsky
Two of the most important CEOs in the world today – Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky – spoke recently with Mike at the Milken Institute’s Future of Health Summit. While Pfizer is already scaling up production and distribution of their mRNA-based vaccine, Gorsky’s company is looking forward to the third-stage clinical trial results for their single dose, vector-based therapy. The unprecedented collaboration fostered at all levels of the biomedical sector has paid dividends, with many more potential treatments to come.
“I'm very proud for what we have been able to achieve,” Albert Bourla tells Mike. “We will see many more companies in the next few weeks and months demonstrating similar successes in their projects against COVID because one vaccine or two vaccines will not be enough for the entire world. The world needs options.”
Conversations with Mike Milken
COVID-19 has changed the way we work and live. In response to the public health emergency, Milken Institute Chairman Michael Milken is engaging a range of industry leaders and medical experts to help us better understand and confront a crisis that has not only altered our current day-to-day but will change the course of how we work, socialize, and fight disease for years to come.
